| Mrs Amanda Ruth Carey, CRNA | |
|
907 E Lamar Alexander Pkwy, Maryville, TN 37804-5015 | |
| (865) 983-7211 | |
| (865) 983-8043 |
| Full Name | Mrs Amanda Ruth Carey |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 7 Years |
| Location | 907 E Lamar Alexander Pkwy, Maryville, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164945275 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Tn Medical Center | Knoxville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Anesthesiologists, Pllc | 8921097197 | 153 |
News Archive
Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).
The University of Tampere and TAYS Heart Hospital use artificial intelligence (A.I.) technologies developed by VTT Technical Research Centre of Finland in the home care of heart patients.
Health care institutions and providers face mounting pressure to wring more value out of every dollar spent on caring for their patients.
China Pharmaceuticals, Inc., one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, today announced record sales for its first quarter ended March 31, 2010. The Company's quarterly report on Form 10-Q was filed on May 17, 2010 with the United States Securities and Exchange Commission.
Treatments available for glioblastoma—malignant brain tumors—have little effect. An international collaboration led by the Laboratoire Neurosciences Paris-Seine tested active ingredients from existing medications and eventually identified one compound of interest, prazosin, on these tumors. Not only did it seem to be effective in this type of cancer, but it also acted on a signaling pathway that is common with other cancers.
› Verified 7 days ago
| Entity Name | University Anesthesiologists, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073619466 PECOS PAC ID: 8921097197 Enrollment ID: O20040511001722 |
News Archive
Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).
The University of Tampere and TAYS Heart Hospital use artificial intelligence (A.I.) technologies developed by VTT Technical Research Centre of Finland in the home care of heart patients.
Health care institutions and providers face mounting pressure to wring more value out of every dollar spent on caring for their patients.
China Pharmaceuticals, Inc., one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, today announced record sales for its first quarter ended March 31, 2010. The Company's quarterly report on Form 10-Q was filed on May 17, 2010 with the United States Securities and Exchange Commission.
Treatments available for glioblastoma—malignant brain tumors—have little effect. An international collaboration led by the Laboratoire Neurosciences Paris-Seine tested active ingredients from existing medications and eventually identified one compound of interest, prazosin, on these tumors. Not only did it seem to be effective in this type of cancer, but it also acted on a signaling pathway that is common with other cancers.
› Verified 7 days ago
| Entity Name | American Anesthesiology Of Tennessee Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609822998 PECOS PAC ID: 9931001922 Enrollment ID: O20040713001364 |
News Archive
Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).
The University of Tampere and TAYS Heart Hospital use artificial intelligence (A.I.) technologies developed by VTT Technical Research Centre of Finland in the home care of heart patients.
Health care institutions and providers face mounting pressure to wring more value out of every dollar spent on caring for their patients.
China Pharmaceuticals, Inc., one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, today announced record sales for its first quarter ended March 31, 2010. The Company's quarterly report on Form 10-Q was filed on May 17, 2010 with the United States Securities and Exchange Commission.
Treatments available for glioblastoma—malignant brain tumors—have little effect. An international collaboration led by the Laboratoire Neurosciences Paris-Seine tested active ingredients from existing medications and eventually identified one compound of interest, prazosin, on these tumors. Not only did it seem to be effective in this type of cancer, but it also acted on a signaling pathway that is common with other cancers.
› Verified 7 days ago
| Entity Name | Maryville Anesthesiologists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336199645 PECOS PAC ID: 0345257606 Enrollment ID: O20060310000282 |
News Archive
Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).
The University of Tampere and TAYS Heart Hospital use artificial intelligence (A.I.) technologies developed by VTT Technical Research Centre of Finland in the home care of heart patients.
Health care institutions and providers face mounting pressure to wring more value out of every dollar spent on caring for their patients.
China Pharmaceuticals, Inc., one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, today announced record sales for its first quarter ended March 31, 2010. The Company's quarterly report on Form 10-Q was filed on May 17, 2010 with the United States Securities and Exchange Commission.
Treatments available for glioblastoma—malignant brain tumors—have little effect. An international collaboration led by the Laboratoire Neurosciences Paris-Seine tested active ingredients from existing medications and eventually identified one compound of interest, prazosin, on these tumors. Not only did it seem to be effective in this type of cancer, but it also acted on a signaling pathway that is common with other cancers.
› Verified 7 days ago
| Entity Name | Lifelinc Anesthesia Ii, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821397233 PECOS PAC ID: 2668658493 Enrollment ID: O20110512000311 |
News Archive
Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).
The University of Tampere and TAYS Heart Hospital use artificial intelligence (A.I.) technologies developed by VTT Technical Research Centre of Finland in the home care of heart patients.
Health care institutions and providers face mounting pressure to wring more value out of every dollar spent on caring for their patients.
China Pharmaceuticals, Inc., one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, today announced record sales for its first quarter ended March 31, 2010. The Company's quarterly report on Form 10-Q was filed on May 17, 2010 with the United States Securities and Exchange Commission.
Treatments available for glioblastoma—malignant brain tumors—have little effect. An international collaboration led by the Laboratoire Neurosciences Paris-Seine tested active ingredients from existing medications and eventually identified one compound of interest, prazosin, on these tumors. Not only did it seem to be effective in this type of cancer, but it also acted on a signaling pathway that is common with other cancers.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Amanda Ruth Carey, CRNA 5325 Mattice Ln, Corryton, TN 37721-4129 Ph: (865) 789-8283 | Mrs Amanda Ruth Carey, CRNA 907 E Lamar Alexander Pkwy, Maryville, TN 37804-5015 Ph: (865) 983-7211 |
News Archive
Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).
The University of Tampere and TAYS Heart Hospital use artificial intelligence (A.I.) technologies developed by VTT Technical Research Centre of Finland in the home care of heart patients.
Health care institutions and providers face mounting pressure to wring more value out of every dollar spent on caring for their patients.
China Pharmaceuticals, Inc., one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, today announced record sales for its first quarter ended March 31, 2010. The Company's quarterly report on Form 10-Q was filed on May 17, 2010 with the United States Securities and Exchange Commission.
Treatments available for glioblastoma—malignant brain tumors—have little effect. An international collaboration led by the Laboratoire Neurosciences Paris-Seine tested active ingredients from existing medications and eventually identified one compound of interest, prazosin, on these tumors. Not only did it seem to be effective in this type of cancer, but it also acted on a signaling pathway that is common with other cancers.
› Verified 7 days ago
Melissa Carol Blackwood, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 907 E Lamar Alexander Pkwy, Maryville, TN 37804 Phone: 865-983-7211 Fax: 865-983-8043 | |
Donna Marie Mcmahan, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 907 E Lamar Alexander Pkwy, Maryville, TN 37804 Phone: 865-983-7211 Fax: 865-983-8043 | |
Crystal E Aycocke, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 907 E Lamar Alexander Pkwy, Maryville, TN 37804 Phone: 865-983-7211 Fax: 865-983-8043 | |
Dr. Chad Andrew Mcclure, DNP Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 907 E Lamar Alexander Pkwy, Maryville, TN 37804 Phone: 865-983-7211 | |
Janet Hudson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 907 E Lamar Alexander Pkwy, Maryville, TN 37804 Phone: 865-983-7211 Fax: 865-450-9374 | |
Michelle D Herschelman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 907 E Lamar Alexander Pkwy, Maryville, TN 37804 Phone: 865-983-7211 Fax: 865-983-8043 | |
Kelsey Keller, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 907 E Lamar Alexander Pkwy, Maryville, TN 37804 Phone: 865-983-7211 |